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and delayed after depolarizations (DADs), in a process 
termed “store overload-induced Ca2+ release” (SOICR).8 
Additionally, SOICR has been associated with apoptosis of 
cardiomyocytes mediated by mitochondrial Ca2+ overload 
or activation of Ca2+-dependent kinases.9–12 In addition to 
the role played by SR Ca2+ overload in digitalis-induced 
arrhythmias, we and others demonstrated that ryanodine 
receptor (RyR2) site Ser2814 phosphorylation by Ca2+ 
calmodulin-dependent protein kinase II (CaMKII) is a key 
determinant of digitalis-induced Ca2+ waves and arrhyth-
mias.5,13 Indeed, pharmacological and genetic interventions 
that prevent CaMKII-dependent RyR2 phosphorylation 
have been effective in reducing digitalis-induced SOICR.5,14 
Interestingly, beyond its arrhythmogenic effect, CaMKII 
has been shown to mediate digitalis-induced apoptosis.6
C ardiotonic glycosides (CG) or digitalis are positive inotropes used in clinical practice and also exist as endogenous ligands of the Na+/K+-ATPase 
(NKA).1 These compounds selectively bind to the NKA 
and cause an increase in intracellular [Na+], which reduces 
Ca2+ extrusion via the sarcolemmal Na+/Ca2+ exchanger 
(NCX), resulting in an increase in sarcoplasmic reticulum 
(SR) Ca2+ load and systolic Ca2+ release. This produces a 
positive inotropic effect, which has motivated their use for 
the treatment of heart failure.2 However, CG have toxic 
effects that limit their clinical use.3 In the heart, they have 
been associated with arrhythmias and loss of cardiac 
myocytes due to apoptosis.4–7 The pro-arrhythmic effects 
have been proposed to occur when the SR Ca2+ storage 
capacity is exceeded, resulting in diastolic SR Ca2+ waves 
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Background: It has been shown that carvedilol and its non β-blocking analog, VK-II-86, inhibit spontaneous Ca2+ release from 
the sarcoplasmic reticulum (SR). The aim of this study is to determine whether carvedilol and VK-II-86 suppress ouabain-induced 
arrhythmogenic Ca2+ waves and apoptosis in cardiac myocytes.
Methods and Results: Rat cardiac myocytes were exposed to toxic doses of ouabain (50 µmol/L). Cell length (contraction) was 
monitored in electrically stimulated and non-stimulated conditions. Ouabain treatment increased contractility, frequency of spontaneous 
contractions and apoptosis compared to control cells. Carvedilol (1 µmol/L) or VK-II-86 (1 µmol/L) did not affect ouabain-induced 
inotropy, but significantly reduced the frequency of Ca2+ waves, spontaneous contractions and cell death evoked by ouabain 
treatment. This antiarrhythmic effect was not associated with a reduction in Ca2+ calmodulin-dependent protein kinase II (CaMKII) 
activity, phospholamban and ryanodine receptor phosphorylation or SR Ca2+ load. Similar results could be replicated in human 
cardiomyocytes derived from stem cells and in a mathematical model of human myocytes.
Conclusions: Carvedilol and VK-II-86 are effective to prevent ouabain-induced apoptosis and spontaneous contractions indicative 
of arrhythmogenic activity without affecting inotropy and demonstrated to be effective in human models, thus emerging as a 
therapeutic tool for the prevention of digitalis-induced arrhythmias and cardiac toxicity.
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Cytosolic Calcium and Cell Shortening Measurements
Myocytes were loaded with 10 μmol/L Fura-2 AM 
(ThermoFisher Scientific) for 12 min. Fura-2 fluorescence 
was measured on an inverted microscope adapted for 
epifluorescence by Ion Optix hardware. The ratio of the 
Fura-2 fluorescence (510 nm) obtained after exciting the 
dye at 340 and 380 nm was taken as an index of Ca2+i. The 
amplitude of the Ca2+ transient induced by rapid application 
of 15 mmol/L caffeine was used to estimate SR Ca2+ 
content.9 Cell shortening was registered by video-detection 
of cell length.9
Detection of Spontaneous Ca2+ Release by Confocal 
Microscopy
Myocytes were loaded with 10 µmol/L Fluo-3 AM 
(ThermoFisher Scientific) and examined using a Zeiss 410 
inverted confocal microscope (LSMTech, Pennsylvania, 
USA). Cells were imaged in line-scan mode along their 
long axis, exciting with the 488 nm line of an argon laser 
and collecting emission at >515 nm.5 Data were analysed 
using the ‘Sparkmaster’ plugin for ImageJ.22
Immunodetection by Western Blot Analysis
Homogenates were prepared from the pulverized ven-
tricular tissue of Langendorff-perfused rat hearts, as previ-
ously described.9 For details, refer to the supplementary 
material.
Human Cardiomyocytes Derived From Induced Pluripotent 
Stem Cells
Induced pluripotent stem cell-derived cardiomyocytes 
(hiPSC-CMs) were obtained by using the monolayer 
differentiation protocol described by Burridge et al.23 For 
this purpose, the FH2.1 induced pluripotent cells were 
used.24 The assessment of the efficiency of cardiac differen-
tiation was performed by using standard flow cytometry to 
determine the percentage of Troponin C+ cells. The cells 
were maintained in Roswell Park Memorial Institute 
(RPMI) medium supplemented with B27 at 37°C and 5% 
CO2 until 35 days after the start of differentiation. Cells 
were used between days 35 and 37.
Human Cardiac Myocyte Mathematical Model
A modified ten Tusscher-Panfilov human ventricular 
myocyte model (TP)25 was used to test the effects promoted 
by VK-II-86, Ouabain and their combination. This model 
has been validated by us and others.26,27 For details, refer 
to the supplementary material.
Assessment of Cell Viability and Apoptosis
Cells were evaluated morphologically, being classified as 
viable or non-viable according to their length-to-width 
ratio (≥3 were considered viable).21 From each culture, 
which was considered as an n equal to 1, at least 8 photo-
graphs per group were taken to count and classify the cells. 
Caspase-3 activity, used as an index of apoptosis, was 
determined using the caspase-3 fluorescent substrate, 
Phiphilux (OncoImmunin; Gaithersburg, MD, USA). 
Briefly, 2.5 µmol/L Phiphilux was added to each culture 
dish at the end of the incubation period and allowed to 
incubate for 1 h at 37°C. Myocytes were gently washed 
once and imaged under a fluorescence microscope.21
Statistical Analysis
Unpaired Student’s t-test and one-way ANOVA followed 
Unfortunately, cardiac-specific CaMKII inhibition is 
not currently available. However, the pharmacological 
modulation of RyR2 has emerged as a therapeutic option 
to prevent arrhythmogenic SR Ca2+ release.15–17 Indeed, 
carvedilol has been shown to have a unique property, not 
shared by other β-blockers, which is to suppress SOICR 
and prevent arrhythmias in mice.16 The antiarrhythmic 
mechanism of carvedilol has been attributed to its action 
on RyR2 gating, particularly the reduction in the duration 
of RyR2 openings.16 Although at present, the specific 
RyR2 binding site for carvedilol has not been established, 
we speculate that a reduction in RyR2 open time could be 
an effective approach to reduce the cardio-toxic effects 
of digitalis.
Carvedilol is the β-blocker of choice for patients with 
heart failure.18–20 Nevertheless, the concentrations required 
to suppress SOICR are higher than those required for 
β-blockade (~1 nmol/L).8 Therefore, SOICR inhibition 
would require high doses of carvedilol, inducing excessive 
β-blockade and bradycardia.21 In contrast, VK-II-86, a 
structural analog of carvedilol has minimum β-blocking 
activity, but retains its capacity to reduce SOICR.16 Thus, 
we hypothesized that VK-II-86 could reduce the incidence 
of arrhythmogenic SR Ca2+ waves in cardiac myocytes 
treated with digitalis. Another aim of this work was to 
test the efficacy of VK-II-86 to reduce digitalis-induced 
cell death.
Methods
All experiments were performed in accordance with the 
Guide for the Care and Use of Laboratory Animals (NIH 
Publication No.85-23, revised 1996) and approved by the 
Institutional Animal Care and Use Committee of La Plata 
University.
Rat Cardiac Myocytes Isolation and Culture
Male Wistar rats (200–300 g) were anaesthetized by an 
intra-peritoneal injection of ketamine (79 mg/kg) and 
diazepam (5 mg/kg), and hearts were excised when plane 
three of phase III of anaesthesia was reached. Plane three 
of phase III of anesthesia was verified by the presence of 
slow deep diaphragmatic breathing, loss of the corneal 
reflex and the absence of tongue retraction. Cardiac 
myocytes were isolated by collagenase-based enzymatic 
digestion, as previously described.21
For culture, isolated cells were re-suspended in Dulbecco’s 
Modified Eagle’s Medium (DMEM) supplemented with 
(in g/L) 0.017 ascorbic acid, 2 BSA, 0.4 L-carnitine, 0.66 
creatine, 0.62 taurine, 50 U/mL penicillin, and 50 U/mL 
streptomycin, and counted. Myocytes were plated at a 
density of ∼2×104 rod-shaped cells/mL into culture dishes 
for 1 h to allow cell attachment. After this period, the 
culture media was changed for a fresh one with or without 
ouabain and the presence or absence of pharmacological 
compounds according to the protocols performed (see 
Results). After 24 h of culture, the cells were photographed 
to assess viability and apoptosis.
Pharmacological Agents
Ouabain, Atenolol and Carvedilol were purchased from 
Sigma-Aldrich; VK-II-86 was synthetized as reported in 
Zhou et al,16 and Ru360 was purchased from Calbiochem, 
USA.
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for an additional 10 min. Consistent with previous results,5 
the typical tracings depicted in Figure 1 show that ouabain 
superfusion produces a positive inotropic effect and 
enhances the incidence of NSE during the non-stimulated 
period compared to untreated control cells. Overall, 
ouabain promoted a 51.9±13.3% increase in contractility 
and increased the number of NSE from 11±2.6 in control 
cells to 71.4±12.1 events/10 min in ouabain-treated cells. 
The tracings further show that pretreatment of cells with 
1 µmol/L of atenolol does not affect either the ouabain-
induced positive inotropic effect or the associated increase 
in NSE. In contrast, pretreatment with 1µmol/L carvedilol 
significantly reduced the ouabain-induced increase of NSE 
without affecting inotropy. The bars graphs in Figure 1 
shows the overall data.
VK-II-86 Prevents Ouabain-Induced Spontaneous 
Contractions Without Affecting the Inotropic  
Response to Ouabain
We next evaluated the effects of VK-II-86 on ouabain 
inotropy and the propensity for NSE. As can be observed 
by the Tukey-Cramer post hoc test were used for statistical 
comparisons when appropriate. Data are expressed as 
mean ± SEM. Differences were considered significant at 
P≤0.05.
Results
Carvedilol Prevents Ouabain-Induced Spontaneous 
Contractile Activity
Previous reports from our and other laboratories demon-
strated that 50 µmol/L ouabain promotes SOICR and its 
associated spontaneous contractions in rat cardiac 
myocytes.5,28 Thus, we compared in the same experimental 
conditions the efficacy of carvedilol and atenolol, 2 different 
β-blockers with and without anti-SOICR properties, to 
abolish ouabain-induced non-stimulated contractile events 
(NSE). The effect of 50 µmol/L ouabain on cell shortening 
and the incidence of NSE were tested in rat cardiomyo-
cytes. Myocytes were field-stimulated at 0.5 Hz and 
superfused with 50 µmol/L ouabain. After 20 min, field 
stimulation was stopped and myocyte length was monitored 
Figure 1.  Carvedilol prevents oua-
bain-induced spontaneous contrac-
tions without affecting its positive 
inotropic effect. Representative 
tracings of cell length showing that 
ouabain (oua) produces a typical 
positive inotropic effect during pac-
ing at 0.5 Hz and a large number of 
spontaneous contractions during 
the non-stimulated period. Control 
cells show stable contraction during 
the 20-min stimulation period and 
few spontaneous events in absence 
of electrical stimulation. Pretreating 
cells with the β-blocker, atenolol, 
did not affect ouabain-induced 
inotropy or spontaneous contrac-
tions. In contrast, carvedilol did not 
prevent ouabain-induced inotropy 
but reduced its spontaneous 
contractile activity. The bar graphs 
show the average results of these 
experiments. Data are presented as 
means ± SEM for 11–12 cells from 
7 to 10 hearts per group. *P≤0.05 
respect to control.
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release triggered by cytosolic Ca2+ released from neighboring 
RyR2 clusters, we examined the effect of VK-II-86 on the 
velocity of SR Ca2+ waves as a measure of RyR2 response 
to cytosolic Ca2+. As shown in Figure 4C, VK-II-86 also 
fails to affect the velocity of Ca2+ waves.
Taken together, these results suggest that the ability of 
VK-II-86 to reduce ouabain-induced arrhythmic activity is 
due to its capacity to reduce RyR2 open time rather than 
to a non-specific reduction in CaMKII activity, SR Ca2+ 
load or the sensitivity of the RyR2 to cytosolic Ca2+.
Human Cardiomyocytes Derived From Induced Pluripotent 
Stem Cells and a Human Computational Cardiomyocyte 
Model Reproduce the Arrhythmic and Inotropic Effects  
of Ouabain and the Antiarrhythmic Action of VK-II-86
Cell shortening was assessed in human-induced pluripotent 
stem cell-derived cardiomyocytes (hiPSC-CMs) between 
days 35 and 37 of culture. Control cells showed stable 
contraction cycles during a 15-min period, and a similar 
pattern was observed in cells treated with 1 µmol/L 
VK-II-86 (not shown). Treatment with 50 µmol/L ouabain 
produced a typical positive inotropic effect that was not 
affected by co-treatment with VK-II-86 (Figure S2). As can 
be observed in Figure 5A, ouabain promoted an increase in 
the frequency of spontaneous beats, whereas VK-II-86 was 
effective in preventing this alteration. To further characterize 
the anti-arrhythmic efficacy of VK-II-86 in a human 
model, we examined the effect of ouabain in the presence 
and absence of VK-II-86 in a mathematical human 
ventricular myocyte model. Figure 5B shows myocyte 
shortening simulation in the presence and absence of 
ouabain with and without VK-II-86. The model predicts 
that ouabain application produces an increase in sarcomere 
shortening and elicits spontaneous contractions during 
the unstimulated phase. Figure 5B further shows that 
pre-treatment with VK-II-86 prevents the occurrence 
of ouabain-induced spontaneous contractions. Similarly, 
simulating CaMKII inhibition significantly reduced the 
number of spontaneous contractions, as shown in the 
in the typical tracings and overall results depicted in 
Figure 2, treating cells with 1 µmol/L VK-II-86 did not 
affect the ouabain-induced positive inotropic effect but 
significantly reduced the incidence of NSE.
VK-II-86 Does Not Affect Ouabain-Induced RyR2 
Phosphorylation or SR Ca2+ Load
Previous reports (by us and others) showed that ouabain-
induced arrhythmias result from SR Ca2+ overload and a 
CaMKII-dependent phosphorylation of the RyR2.5,14 To 
assess whether the antiarrhythmic effects of VK-II-86 are 
due to reversal of these alterations, we examined the effect 
of VK-II-86 on ouabain-induced CaMKII activity, RyR2 
phosphorylation and SR Ca2+ load. Figure 3 shows typical 
blots and average results indicating that ouabain-induced 
CaMKII activity (p-CaMKII), oxidation (OxiCaMKII); 
phosphorylation of phospholamban (PLN; residues Serine 
16 and Threonine 17) and the RyR2 (residues Serine 2808 
and 2814) are preserved in the presence of VK-II-86.
The traces in Figure 4A show the effect of ouabain, in 
the absence and presence of VK-II-86, on the caffeine-
induced Ca2+ transients, performed to evaluate SR Ca2+ 
content. As can be observed in the typical traces and 
average results, VK-II-86 fails to affect caffeine-induced 
SR Ca2+ release in ouabain-treated cells.
Consistent with the observation that VK-II-86 prevents 
spontaneous contractions that arises from Ca2+ waves, 
Figure 4B depicts typical confocal images and average 
results showing that ouabain significantly increases Ca2+ 
wave frequency compared to untreated cells, and that this 
increase is prevented when ouabain is administered in the 
presence of VK-II-86. In addition, the overall results 
show that VK-II-86 prevents the ouabain-induced increase 
in Ca2+ spark frequency without affecting sparks mor-
phology. This suggests that the effect of VK-II-86 on RyR2 
gating directly has an effect on the probability of Ca2+ 
spark formation, which ultimately reduces Ca2+ waves 
frequency.
Finally, as SR Ca2+ waves represent propagated Ca2+ 
Figure 2.  VK-II-86 does not affect 
ouabain inotropy but prevents the 
increase in spontaneous contractile 
activity. Representative tracings of 
cell length showing that in the pres-
ence of 1 µmol/L VK-II-86, ouabain 
(oua) produces a positive inotropic 
effect without increasing in sponta-
neous contractile activity during the 
non-stimulated period. The bar graph 
depicts overall data showing the 
effect of ouabain in the presence 
and absence of VK-II-86 on cell 
shortening and on the number of 
non-stimulated contractile events 
(NSE). Ouabain solution was sup-
plemented with Dimethyl sulfoxide 
(DMSO) to account for the vehicle 
used in VK-II-86 solutions. Data are 
presented as means ± SEM for n=12–
18 cells from 7 to 10 hearts per 
group. *P≤0.05 respect to control.
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ouabain-induced increase in SR Ca2+ load in the presence 
of VK-II-86 or CaMKII inhibition.
Carvedilol and VK-II-86 Prevent Ouabain-Induced Cell Death
In previous reports, we and others demonstrated that 
typical traces and the bar graphs of overall results. The bar 
graphs further show the inotropic response to ouabain 
(25% increase in sarcomere shortening) and its preservation 
in the presence of either VK-II-86 (22%) or CaMKII 
inhibition (25%). This is consistent with the preserved 
Figure 3.  Effect of ouabain in the 
presence and absence of VK-II-86 on 
Ca2+ calmodulin-dependent protein 
kinase II (CaMKII) activity. Represen-
tative blots and overall results from 
homogenates of hearts treated 
with ouabain (oua) in the absence 
or presence of VK-II-86 probed 
with antibodies for phosphorylated 
CaMKII (pCaMKII), for the oxidation 
site of CaMKII, Methionine 281/282 
(oxiCaMKII), for RyR2 phosphoryla-
tion sites, Ser2808 and Ser2814, and 
for phospholamban (PLN) phos-
phorylation sites, Ser16 and Thr17. 
Results are presented as mean ± SEM 
(n=3–5 for each group). Ouabain 
solution was supplemented with 
Dimethyl sulfoxide to account for the 
vehicle used in VK-II-86 solutions.
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have suggested that under pathological conditions, Ca2+ 
leaking from the SR can be shuttled into the mitochondria 
via the Ca2+ uniporter, resulting in mitochondrial Ca2+ 
overload, which triggers the apoptotic cascade.11,30 Figure 6A 
depicts representative images and overall results, showing 
chronic exposure (24 h) to sub-arrhythmogenic concen-
trations of ouabain (2 µmol/L) promote cardiomyocyte 
apoptosis.6,29 Although the mechanisms underlying 
ouabain-induced cardiomyocyte death are not fully under-
stood, previous reports from our and other laboratories 
Figure 4.  Effect of ouabain in the presence and absence of VK-II-86 on sarcoplasmic reticulum (SR) Ca2+ load and SR Ca2+ 
release. (A) Typical tracings and overall results of caffeine pulses performed to estimate SR Ca2+ load in rat myocytes in the 
presence of either ouabain or ouabain+VK-II-86. The bar graph shows the average values of these experiments. Data are 
presented as means ± SEM for 8 cells from 4 hearts per group. (B) Original confocal line-scan images of myocytes in the absence 
of ouabain (cont) or either in the presence of ouabain (oua) or ouabain+VK-II-86. The bar graph indicates that ouabain significantly 
increased Ca2+ spark and wave frequency and it was prevented by VK-II-86. Characterization of sparks morphology is presented 
by the evaluation of Amplitude, Full Width at Half Maximum (FWHM) and Full duration at Half Maximum (FDHM). Treatment with 
VK-II-86 alone has not significantly changed the evaluated parameters (not shown). Data are presented as means ± SEM for 8–12 
cells from 4 to 6 hearts per group. *P≤0.05 with respect to the control. (C) Typical example of a line-scan image with the slopes of 
the Ca2+ wave front from a cell treated with 50 µmol/L ouabain highlighted by a white line; this slope was analysed in µm/s. Similar 
experiments performed in the presence of ouabain+VK-II-86 did not change wave propagation velocity (not shown). The graph 
on the right depicts the overall results as means ± SEM. Data are presented as means ± SEM for 8–12 cells from 4 to 6 hearts per 
group. Control and ouabain solutions were supplemented with Dimethyl sulfoxide to account for the vehicle used in VK-II-86 solutions.
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cardiac myocytes treated with toxic doses of ouabain; (2) 
based on the use of 2 human cardiomyocyte models, our 
results may be extrapolated to human ventricular cardio-
myocytes; (3) VK-II-86 does not affect the ouabain-induced 
increase in CaMKII activity, PLN and RyR2 phosphory-
lation or SR Ca2+ load, suggesting that its antiarrythmic 
effect is due to modulation of RyR2 gating properties; (4) 
VK-II-86 does not blunt the ouabain-induced positive 
inotropic effect; and (5) VK-II-86 is able to prevent ouabain-
induced cardiomyocyte death.
Diastolic SR Ca2+ waves activate the inward NCX 
current (INCX) causing DADs. Threshold-surpassing DADs 
have been proposed to underlie arrhythmias in catechol-
aminergic polymorphic ventricular tachycardia (CPVT), 
heart failure and digitalis toxicity.31 Indeed, previous reports 
from our and others have shown that an increase in SR 
that 10 µmol/L of the mitochondrial Ca2+ uniporter 
inhibitor, Ru360, is able to prevent ouabain-induced 
apoptosis, supporting that mitochondrial Ca2+ overload is 
involved in ouabain cytotoxicity. In addition, Figure 6B 
shows that ouabain-induced cell death can be prevented by 
carvedilol and VK-II-86. These results indicate that reducing 
RyR2-mediated Ca2+ release is effective to prevent 
ouabain-induced cell death. Control experiments showed 
that 10 µmol/L Ru360, 1 µmol/L carvedilol or 1 µmol/L 
VK-II-86 did not, per se, affect cell viability (not shown).
Discussion
Major findings of this study are: (1) carvedilol and its analog, 
VK-II-86, reduce the propensity for arrhythmogenic Ca2+ 
waves and the associated spontaneous contractions in rat 
Figure 5.  Effect of ouabain in the 
presence and absence of VK-II-86 
on human induced pluripotent stem 
cells (IPSC) and a human cardio-
myocyte mathematical model. (A) 
Representative tracings and aver-
age results of induced pluripotent 
stem cell-derived cardiomyocytes 
(hiPSC-CMs) shortening showing 
that after 15 min, ouabain (oua) 
increases spontaneous contraction 
frequency. Pretreating cells with 
VK-II-86 did not affect basal spon-
taneous activity (data not shown), 
but prevented ouabain-induced 
increase in spontaneous beating 
rate. Data are presented as means ± 
SEM from 9 to 19 cells from at least 
3 differentiation events. *P≤0.05 with 
respect to control. (B) Model-simu-
lated half-sarcomere length tracings 
representing control, ouabain, VK-
II-86+ouabain and KN93+ouabain 
conditions. Ouabain increased myo-
cyte shortening and elicited spon-
taneous contractile events. These 
arrhythmic episodes were similarly 
reduced by VK-II-86 and KN93, 
without reducing the inotropic effect 
of ouabain. The bar graphs show 
the average results.
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digitalis.3 In an attempt to enhance the safety of these 
compounds, we previously suggested that CaMKII inhibi-
tion could prevent digitalis-induced arrhythmias.5 However, 
the ubiquitous nature of CaMKII expression and its effects 
on different targets precludes its inhibition as a therapeutic 
Ca2+ load and in CaMKII-dependent RyR2 phosphoryla-
tion contributes to the enhanced diastolic SR Ca2+ release 
that generates the DADs associated with digitalis treat-
ment.5,14 These arrhythmias and toxic effects such as 
cardiomyocyte death have limited the therapeutic use of 
Figure 6.  Carvedilol and VK-II-86 prevent ouabain-induced cell death. (A) representative images and overall results of myocyte 
viability and caspase-3 activity of myocytes cultured for 24 h in culture medium alone (cont) or culture medium supplemented with 
2 µmol/L ouabain (oua) either in the absence or the presence of 10 µmol/L Ru360 (n=5 per group). (B) Representative images 
and overall results of myocyte viability and caspase-3 activity of myocyte in culture medium alone (cont) or culture medium 
supplemented with 2 µmol/L ouabain (oua) either in the absence or presence of 1 µmol/L carvedilol (carve) or 1 µmol/L VK-II-86. 
These images and the overall data depicted in the bar graphs show that carvedilol and VK-II-86 prevent ouabain-induced cell 
death (n=5 per group). *P≤0.05 with respect to the control.
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Ca2+ wave frequency (Figure 4B), it failed to affect Ca2+ 
wave velocity (Figure 4C). Ca2+ waves represent SR Ca2+ 
release triggered by cytosolic Ca2+ released from neighboring 
RyR2 clusters. Therefore, the velocity of Ca2+ waves can 
be used as an index of RyR2 sensitivity to cytosolic Ca2+.35 
Thus, our results suggest that VK-II-86-antiarrhythmic 
actions are not due to a reduction in RyR2 sensitivity to 
cytosolic Ca2+. These results are consistent with previous 
evidence showing that the antiarrhythmic mechanism of 
carvedilol and its analogs is mediated by their direct action 
on RyR2-mediated SOICR.16
Carvedilol and VK-II-86 Do Not Affect the Inotropic 
Response of Ouabain-Treated Cardiac Myocytes
One of the most important therapeutic benefits of digitalis 
is their capacity to increase intracellular Ca2+ with the 
consequent development of a positive inotropic effect. 
Thus, prevention of arrhythmias during digitalis treatment 
should not blunt the development of their inotropic effect. 
Interestingly, carvedilol and VK-II-86 reduced ouabain-
induced arrhythmias, without affecting the ouabain-induced 
positive inotropic effect (Figures 1,2).
The possibility of using an Food and Drug Administra-
tion (FDA)-approved drug such as carvedilol to target 
RyR2 in combination with cardiac glycosides to treat 
heart failure patients is promising. However, a possible 
limitation is that the concentration of carvedilol required 
to reduce RyR2 open time is high, and its β-blocking action 
would produce undesirable bradycardia. The lack of 
β-blocking effect of VK-II-86 represents a favorable 
feature and suggests that it could be used as an adjunct to 
digitalis therapy.
Human Cellular and Mathematical Models Support 
Antiarrhythmic Actions of VK-II-86
To enhance the translational relevance of our findings, 
we performed experiments in hiPSC-CMs, which exhibit 
molecular and functional properties of human cardiac 
cells.36,37 Importantly, ouabain-induced arrhythmias have 
been detected in hiPSC-CMs, suggesting that these cells 
can be used to analyze clinically relevant outcomes.38 
Similar to rat cardiomyocytes, VK-II-86 prevented the 
ouabain-induced increase in spontaneous contractile activity 
of hiPSC-CMs without affecting inotropy, suggesting that 
VK-II-86 may be effective in humans (Figures 5A,S2).
We further corroborated these findings in a mathematical 
model that simulates human cardiac Excitation-contraction 
coupling. The model reproduced the positive inotropic 
effect induced by ouabain, together with the arrhythmic 
activity (Figure 5B). Furthermore, the model predicts that 
a reduction of RyR2 open time by VK-II-86 is effective to 
reduce the ouabain-induced arrhythmic events in human 
ventricular myocytes. Taken together, these results provide 
evidence supporting the protective role of VK-II-86 against 
ouabain-induced arrhythmias in a human model of digitalis 
toxicity.
Carvedilol and VK-II-86 Prevent Ouabain-Induced Cardiac 
Myocyte Death
Activation of CaMKII is a common intermediate of 
diverse death stimuli that induce apoptosis in cardiac 
cells.6,11 Consistently, we have demonstrated that CaMKII 
activity mediates ouabain-induced myocyte apoptosis.6 
Interestingly, we recently reported that rapid pacing-induced 
apoptosis, also CaMKII dependent, can be prevented by 
tool. Albeit not impossible, pharmacological CaMKII 
inhibition would require cardiac-specific CaMKII inhibi-
tors, which are at present unavailable. The involvement of 
RyR2 in the development of arrhythmias during digitalis 
toxicity allows us to postulate an alternative, which is 
to directly target RyR2 function. We are aware of one 
report that tested this approach in the setting of digitalis 
treatment.32 Using the multi-channel blocker, JTV-519, 
which stabilizes RyR2-FK506 binding protein (FKBP) 
interaction, Sacherer et al were able to reduce SR Ca2+ 
leak. However, JTV-519 impaired the positive inotropic 
response to digitalis due to inhibitory effect on the L-type 
Ca2+ current.32
Recently, carvedilol has been shown to reduce the 
RyR2 mean open time, thus suppressing spontaneous SR 
Ca2+ release in a mouse model of CPVT.16 Moreover, the 
antiarrhythmic effects of carvedilol were shared by its 
non-β-blocking analog, VK-II-86.16 These results, prompted 
us to evaluate whether carvedilol and VK-II-86 were able 
to prevent arrhythmogenic SR Ca2+ release during digitalis 
toxicity. Using the number of NSE as an index of diastolic 
SR Ca2+ release, we observed that although not affecting 
basal contractility (not shown), carvedilol and VK-II-86 
significantly reduce the arrhythmogenic substrate induced 
by ouabain without blunting its positive inotropic effect 
(Figures 1,2).
Mechanisms Underlying VK-II-86-Dependent Ca2+ Waves 
Inhibition
Recently, Zhou et al reported that VK-II-86 shortens the 
duration but increases the frequency of RyR2 channel 
opening.16 This could affect how Ca2+ leaks out the SR by 
reducing intra-cluster RyR2 recruitment, inter-cluster RyR2 
recruitment or both. In light of our results, it seems that 
VK-II-86 reduces intra-cluster RyR2 recruitment as it 
prevented ouabain-induced increase in spark frequency 
and secondarily reduced Ca2+ wave incidence. This inter-
pretation is compatible with a reduction in spark-mediated 
SR Ca2+ leak without significant changes in SR Ca2+ 
content. Consistently, we showed that VK-II-86 was able 
to reduce the ouabain-induced increase in wave frequency 
without affecting SR Ca2+ content (Figure 4A,B).
Previous reports from our laboratory showed that 
CaMKII-dependent RyR2 phosphorylation is a crucial 
determinant of digitalis-induced arrhythmias.5,33 More 
recently, Ho et al proposed that digitalis-induced arrhyth-
mias occur due to oxidative activation of CaMKII, which 
leads to phosphorylation of the RyR2 at site Ser2814.14 
Supporting this conclusion, transgenic mice, in which the 
Ser2814 site of the RyR2 cannot be phosphorylated (S2814A 
mice), were resistant to digitoxin-induced arrhythmias, 
providing unequivocal evidence of the causal role of S2814 
phosphorylation in the digitalis-induced RyR2 dysfunc-
tion.14 This last observation also suggests that RyR2 
oxidation does not contribute to the arrhythmic effect of 
digitalis. Nevertheless, carvedilol has been shown to have 
acute antioxidant activity on RyR2,34 and we cannot 
exclude that this antioxidant activity could explain part 
of the antiarrhythmic action of this compound and its 
structurally similar analog. Indeed, our results showing 
that VK-II-86 does not affect ouabain-induced CaMKII 
autophosphorylation (p-CaMKII) or its oxidation state 
(Oxi-CaMKII) (Figure 3) suggests that the antiarrhythmic 
effect of VK-II-86 is due to a direct action on RyR2.
In addition, although VK-II-86 reduced ouabain-induced 
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targeting RyR2 with carvedilol and VK-II-86.9 Considering 
that ouabain-induced cytotoxicity involves SR Ca2+ release 
trough RyR2, which could drive mitochondrial Ca2+ 
overload and cell death, we hypothesized that reducing 
RyR2 open time could prevent ouabain-induced cell death. 
Confirming the role of mitochondrial Ca2+ overload in 
ouabain-induced cell death, cells treated with the mitochon-
drial Ca2+ uniporter inhibitor, Ru360, were protected 
from ouabain cytotoxicity (Figure 6A). In addition, we 
show herein that carvedilol and VK-II-86 prevented 
ouabain-induced apoptosis, suggesting additional benefits 
of reducing RyR2-mediated spontaneous Ca2+ release 
during digitalis treatment (Figure 6B). Interestingly, chronic 
carvedilol incubation has been shown to have antioxidant 
activity in cardiac myocytes.34 Thus, the antioxidant capacity 
of carvedilol could be additionally beneficial to prevent 
ouabain-induced cell death.
In summary, our results demonstrate that carvedilol and 
VK-II-86 are able to prevent ouabain-induced arrhythmias 
and myocyte death, indicating that these compounds, in 
particular VK-II-86, could be a promising approach to 
enhance the safety of digitalis therapy.
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